Seisuke Nagase

1.2k total citations · 1 hit paper
18 papers, 841 citations indexed

About

Seisuke Nagase is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Seisuke Nagase has authored 18 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Seisuke Nagase's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (6 papers). Seisuke Nagase is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (6 papers). Seisuke Nagase collaborates with scholars based in Japan and United States. Seisuke Nagase's co-authors include Kōichi Goto, Nobuyuki Yamamoto, Takashi Seto, Kazuhiko Nakagawa, Takeharu Yamanaka, Shinji Atagi, Isamu Okamoto, Makoto Maemondo, Noboru Yamamoto and Masahiro Fukuoka and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Journal of Thoracic Oncology.

In The Last Decade

Seisuke Nagase

17 papers receiving 826 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 561 citations Takashi Seto, Terufumi Kato et al. The Lancet Oncology profile →

Peers

Seisuke Nagase

PRM

ONCOL

SURGE

Kristina Lamberg Sweden

Naoki Furuya Japan

Ruqin Chen United States

Francesca Casaluce Italy

Karl Kölbeck Sweden

Assunta Sgambato Italy

Joan Lucca United States

Kosei Tajima Japan

Yun Fan China

Mark R. Olsen United States

Kristina Lamberg Sweden

Seisuke Nagase

427 ×0.6

PRM

414 ×0.7

ONCOL

194 ×1.1

139 ×1.3

62 ×1.1

SURGE

Citations per year, relative to Seisuke Nagase Seisuke Nagase (= 1×) peers Kristina Lamberg

Countries citing papers authored by Seisuke Nagase

Since Specialization

Citations

This map shows the geographic impact of Seisuke Nagase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seisuke Nagase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seisuke Nagase more than expected).

Fields of papers citing papers by Seisuke Nagase

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seisuke Nagase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seisuke Nagase. The network helps show where Seisuke Nagase may publish in the future.

Co-authorship network of co-authors of Seisuke Nagase

This figure shows the co-authorship network connecting the top 25 collaborators of Seisuke Nagase. A scholar is included among the top collaborators of Seisuke Nagase based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seisuke Nagase. Seisuke Nagase is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Nishio, Makoto, Shinji Atagi, Kōichi Goto, et al.. (2023). Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer. Translational Lung Cancer Research. 12(6). 1167–1184. 3 indexed citations

Furukawa, Asuka, Yuichi Tamura, Akio Kawamura, et al.. (2022). Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. Journal of Cardiology. 81(1). 63–67. 21 indexed citations

Takekoshi, Tomonori, Rina Nakajima, Asuka Furukawa, et al.. (2020). An anti-RNA polymerase III antibody-positive systemic sclerosis patient with thymic carcinoma whose digital ulcers healed during treatment with macitentan and sildenafil for pulmonary arterial hypertension. European Journal of Dermatology. 30(2). 207–209.

Nakahara, Yoshiro, Yukio Hosomi, Masahiko Shibuya, et al.. (2019). Multicenter study of zoledronic acid administration in non‑small‑cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. Molecular and Clinical Oncology. 11(4). 349–353. 4 indexed citations

Taira, Tetsuhiko, Kiyotaka Yoh, Seisuke Nagase, et al.. (2018). Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 81(3). 565–572. 8 indexed citations

Naoki, Katsuhiko, Yuichiro Takeda, Kenzo Soejima, et al.. (2017). A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab. Oncology Letters. 13(5). 3285–3290. 2 indexed citations

Shukuya, Takehito, Takeharu Yamanaka, Takashi Seto, et al.. (2015). Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. The Lancet Oncology. 16(16). 1630–1638. 65 indexed citations

Kudo, Yujin, Yoshihisa Shimada, Hisashi Saji, et al.. (2015). Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System. Clinical Lung Cancer. 16(6). e213–e221. 16 indexed citations

Shukuya, Takehito, Takeharu Yamanaka, Takashi Seto, et al.. (2015). Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.. Journal of Clinical Oncology. 33(15_suppl). 8004–8004. 3 indexed citations

10.

Seto, Takashi, Terufumi Kato, Makoto Nishio, et al.. (2014). Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. The Lancet Oncology. 15(11). 1236–1244. 561 indexed citations breakdown →

11.

Kato, Terufumi, Takashi Seto, Makoto Nishio, et al.. (2014). Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.. Journal of Clinical Oncology. 32(15_suppl). 8005–8005. 15 indexed citations

12.

Kogure, Yoshihito, Masahiko Ando, Hideo Saka, et al.. (2013). Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L. Journal of Thoracic Oncology. 8(6). 753–758. 37 indexed citations

13.

Hashimoto, Hironobu, Takeharu Yamanaka, Yasuhiro Shimada, et al.. (2013). Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.. Journal of Clinical Oncology. 31(15_suppl). 9621–9621. 15 indexed citations

14.

Ikeda, Norihiko, Seisuke Nagase, & Tatsuo Ohira. (2009). Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.. PubMed. 15(3). 144–9. 11 indexed citations

15.

Niho, Seiji, Hirofumi Fujii, Koji Murakami, et al.. (2007). Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer. 57(3). 328–333. 44 indexed citations

16.

Yoshimura, Kotaro, et al.. (2005). [A case of pulmonary infection due to Mycobacterium simiae].. PubMed. 43(1). 32–6. 4 indexed citations

17.

Fukutomi, Yasushi, Hisataka Moriwaki, Seisuke Nagase, et al.. (2002). Metachronous colon tumors: risk factors and rationale for the surveillance colonoscopy after initial polypectomy. Journal of Cancer Research and Clinical Oncology. 128(10). 569–574. 21 indexed citations

18.

Okuno, Masataka, Takuji Tanaka, Seisuke Nagase, et al.. (1998). Suppressive effect of low amounts of safflower and perilla oils on diethylnitrosamine‐induced hepatocarcinogenesis in male F344 rats. Nutrition and Cancer. 30(3). 186–193. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact